Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report) and Century Therapeutics (IPSC – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jazz Pharmaceuticals (JAZZ)
In a report released today, Ami Fadia from Needham maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $235.00. The company’s shares closed last Tuesday at $173.83.
According to TipRanks.com, Fadia is a 5-star analyst with an average return of
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $228.50, representing a 32.4% upside. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $191.00 price target.
See today’s best-performing stocks on TipRanks >>
Century Therapeutics (IPSC)
Century Therapeutics received a Buy rating from TD Cowen analyst Phil Nadeau today. The company’s shares closed last Tuesday at $2.13.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of
Currently, the analyst consensus on Century Therapeutics is a Strong Buy with an average price target of $5.30.
